Press Room

Event

AAPS 2018

Start
Sunday, November 04, 2018 - 00:00
End
Wednesday, November 07, 2018 - 00:00
Location: Washington DC, United States
Booth Number: 2309
Spray Drying Development by Design | Hovione

If you would like to discuss with us your projects and to find how Hovione can help, schedule a meeting with us. Adam Neunuebel will be pleased to meet you.

adam-neunuebel-photo

Adam Neunuebel

Head of Business Development

 

HOVIONE POSTERS

Poster name / Presentation Authors / Presenter Poster # and Presenter Presentation  Date / Time
Use of Hot Melt Extrusion for the production of controlled release diclofenac formulation with PLGA/PLA - standard and accelerated IVR methods João Henriques #M1030-07-056 - João Henriques Monday, Nov 5

10:30 – 11:30 
Microfludization for Solubility Enhancement – One Technology Fits All Fonseca, T., Duarte, I., Vicente, J.,

Temtem, M		 #M1430-10-075 - Iris Duarte Monday, Nov 5

14:30 – 15:30 
Performance evaluation during process development: different techniques, complementary results Luis Sousa #M1530-07-049 - Luis Sousa Monday, Nov 5

15:30 – 16:30 
Identify your limits: definition of Spray drying Tout based on a novel methodology to measure powder stickiness  Luis Sousa #T1130-07-050 - Luis Sousa Tuesday, Nov 6

11:30 – 12:30 
Laser diffraction analysis of supersaturated solutions and application to screening of amorphous dispersions  Luis Sousa #T1230-07-049 - Luis Sousa Tuesday, Nov 6

12:30 – 13:30 
Effect of Surfactant Level on Properties of Celecoxib Amorphous Solid Dispersion  Fan Meng, Rui Ferreira,

Feng Zhang		 #T1330-09-065  Tuesday, Nov 6

13:30 – 14:30 
Miniaturized methodology of polymer screening for spray dried dispersions  Luis Sousa #W0930-07-050 - Luis Sousa Wednesday, Nov 7

9:30 – 10:30 
New formulation screening approach to optimize tablet disintegration profiles based on cloud/precipitation point measurement João Henriques #W1030-13-097 - João Henriques Wednesday, Nov 7

10:30 – 11:30 
How to develop an amorphous solid dispersion in tablets with less than 30 g API João Henriques #W1030-13-100 - João Henriques Wednesday, Nov 7

10:30 – 11:30 
DPI Carrier-Based Formulation Scale-Up: A Statistical Analysis Approach Marcio Temtem, Filipa Maia,

Isabel Lopes, Luis Sousa,

Maria Braga, Nuno Neves		 #W1230-09-068 - Eunice Costa  Wednesday, Nov 7

12:30 – 13:30 
Simulating the Pulmonary Route: From Actuation to Absoption Beatriz Fernandes, Maria Malmlof,

Marcio Temtem,

M. Luisa Corvo,

Per Gerde, Eunice Costa		 #W1230-09-065  Wednesday, Nov 7

12:30 – 13:30 
Molecular Interactions between Rafoxanide and Povidone for Amorphous Solid Dispersion Preparation and Feng Zhang. Fan Meng, Zhifeng Jing,

Yongchao Su, Rui Ferreira, Pengyu Ren 		    

 

 

 

 

 

 

 

 

 

 

 

 

 

You might be also interested in

 

 

Also in the Press Room

See All

Aim to accelerate drug development and production with new technologies. By: Charlie Sternberg Hovione, an international integrated pharmaceutical development and manufacturing organization, and Microinnova Engineering, a leader in continuous process intensification, have partnered to advance the development of multi-purpose, plug-and-play modular equipment for flow chemistry. The companies will work together to test Microinnova’s modular manufacturing equipment, which is designed to offer greater flexibility, easier scalability, enhanced efficiency, and sustainable practices in active ingredient production, in an industrial setting. Together, the companies aim to accelerate process development, facilitate a seamless transition from lab to large-scale manufacturing, and ultimately reduce the time to market for pharmaceutical customers. “This collaboration with Microinnova underscores Hovione’s commitment to innovation in pharmaceutical manufacturing, with flow chemistry playing an important role in our long-term drug substance strategy,” said Dr. Jean-Luc Herbeaux, CEO of Hovione. “This partnership will allow us to shape and validate emerging continuous manufacturing technologies, which can potentially accelerate drug development and production.” Dr. Dirk Kirschneck, Founder and Strategic Director at Microinnova, added, “This partnership reflects our shared vision to deliver modular manufacturing technologies that support pharmaceutical innovation and manufacturing excellence. We are proud to join forces with Hovione to showcase the capabilities of our next-generation modular equipment in a dynamic CDMO environment, demonstrating its versatility for multi-purpose manufacturing.”   Read the full article on ContractPharma.com  

Press Clipping
Contract Pharma, 24 September 2025

Hovione, Microinnova Partner to Test Modular Manufacturing Equipment

Sep 24, 2025

Hovione is a global contract development and manufacturing organization (CDMO) company founded in Portugal in 1959. With approximately 2,400 team members worldwide, the company provides comprehensive services for drug substances, drug intermediates, and drug products in countries around the world. Japan in particular plays a very important role in Hovione's global strategy, and in 2017 it established a Japanese subsidiary in Osaka. The company plans to actively invest in further strengthening its organization and recruiting personnel. With development labs strategically located in Lisbon, Portugal, and New Jersey, USA, Hovione consistently provides superior solutions tailored to complex pharmaceutical challenges. Hovione is recognized globally for its scientific excellence, technological innovation, and customer-centric and integrated approach. Leveraging cutting-edge capabilities in chemical synthesis, particle engineering, and formulation development, the company supports its partners throughout the entire pharmaceutical life cycle.   Read the full article in Japanese Read the article translated in English   Visit the Yakuji Nippo online      

Press Clipping
Yakuji Nippo Magazine, 2 July 2025

Solving Complex Pharmaceutical Challenges

Jul 10, 2025

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping
Pharmiweb.com, 25 June 2025

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025

Also in Events

See All